Skip to content

MultiSPectral fLuorescence Imaging as a Tool to separate healthy and disease related lymphatic anatomies during lymph node dissections in prostate cancer.

MultiSPectral fLuorescence Imaging as a Tool to separate healthy and disease related lymphatic anatomies during lymph node dissections in prostate cancer. - SPLIT study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON54192
Enrollment
28
Registered
2021-10-28
Start date
2022-03-24
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Sponsors

Antoni van Leeuwenhoek Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Male, aged >= 18 years. * WHO performance status 0,1, or 2. * Written informed consent. * Histopathologically confirmed adenocarcinoma of the prostate * Increased risk of nodal metastases according to the MSKCC nomogram (> 7%) * Scheduled for surgical (laparoscopic) prostatectomy including ePLND * Suitable for RP and ePLND, as per institutional guidelines

Exclusion criteria

Exclusion criteria: * Prostate cancer patients with prior abdominal or inguinal surgery * History of allergy to iodine, food or medicinal induced urticaria, asthma, eczema, or aller-gic rhinitis * Hyperthyroid or thyroidal adenoma * Kidney insufficiency * History of oversensitivity to FLUORESCITE composites * Patients using beta-blockers

Design outcomes

Primary

MeasureTime frame
- Determine the technical feasibility of using multispectral fluorescence imaging to distinguish between two lymphatic drainage patterns LNLower limb/abdominal wall (fluorescein) and LNprostate (ICG-99mTc- nanocolloid)) in prostate cancer patients scheduled for RALP + ePLND + SN us-ing the Firefly Si laparoscope (da Vinci Si®) and/or Image 1 HUB HD + D-light P (Karl Storz) system. - Determine whether and where the lymphatic drainage profile of the lower limbs/abdominal wall converge with the drainage profile of the primary tumor: are there lymph nodes containing both fluorescein and ICG-99mTc- nanocolloid

Secondary

MeasureTime frame
- Correlate pathological tumour findings in the excised nodal specimens with the presence of ICG-99mTc- nanocolloid or fluorescein (or lack thereof) in order to assess if separation of the lymphatic drainage pathways in fact also means that no metastases are found in LNLower limb/abdominal wall (fluorescein). - Determine whether fluorescein is also found in lymph nodes in ePLND template on contralateral side of injection in lower limb/abdominal wall - Determine the anatomical relationship between the lymphatic drainage profile of the lower limbs/abdominal wall and the sentinel node of the primary tumor - Determine lymph fluid leakage by measuring this during surgery as this can be a predictive factor for complications: o Leakage yes/no? o Yes: 1cm from lymphnode? *

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)